logo
logo

Neuroelectrics Raises $17.5M To Advance Clinical Trials For The Treatment Of Epilepsy And Major Depressive Disorder With A New Platform For Treating Brain Dysfunction

May 04, 2021•over 4 years ago

Amount Raised

$17.5 Million

Cambridge

Description

Neuroelectrics, a pioneer in brain stimulation technologies and therapies, has raised $17.5M in a Series A financing led by Morningside Ventures. The funds will be used to further develop Neuroelectrics’ non-invasive transcranial electrical stimulation (tES) therapeutic platform and to advance clinical trials in refractory focal epilepsy and at-home treatment of refractory depression.

Company Information

Company

Neuroelectrics

Location

Cambridge, Maryland, United States

About

Neuroelectrics is developing a therapeutic platform that uses neuromodulation for the treatment of a range of neurological and psychiatric disorders. The platform combines safe and proven neuromodulation capabilities with remote-controlled delivery and personalized treatment protocols to restore and maintain brain health. Based in Cambridge, Massachusetts and Barcelona, Neuroelectrics has an expanding pipeline of computationally driven solutions for neurologic and psychiatric disease. Visit www.neuroelectrics.com.

Funding Insights

Based on industry data
Tech investment trends
83% of B2B companies plan digital investments, with 79% prioritizing customer experience tech